Pharmaceuticals News and Research

RSS

NeoStem completes merger with Progenitor Cell Therapy

NeoStem, Inc. and Progenitor Cell Therapy LLC announced today the closing of their previously announced merger transaction.

21 Jan 2011

ACT Biotech releases telatinib Phase 2 trial data for metastatic stomach cancer

ACT Biotech, a biopharmaceutical company focused on the development of highly targeted, oral therapeutics for the treatment of cancer, today released data on additional analysis of the Phase 2 clinical trial of telatinib in patients with metastatic stomach cancer that further supports the highly-potent nature of the antiangiogenic agent.

21 Jan 2011

Alliqua completes transdermal pain patch initial study for treatment of PHN

Alliqua, an advanced biomedical products company focused on the development and manufacturing of proprietary drug delivery and liver health technologies, announced today the successful completion of its initial study for the transdermal pain patch project.

20 Jan 2011

Routine rotavirus vaccine shows a significant drop in diarrhea cases: Study

A latest study has shown that the rotavirus vaccines have helped drastically reduce hospital visits around the world. Rotavirus can lead to fatal cases of diarrhea in children and causes half a million deaths in kids under five each year around the world. Developing countries are particularly at risk.

20 Jan 2011

FDA accepts Vertex's telaprevir NDA for six-month Priority Review

Vertex Pharmaceuticals Incorporated announced today that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for telaprevir and granted the company's request for six-month Priority Review. Telaprevir is Vertex's lead medicine in development for people with genotype 1 chronic hepatitis C.

20 Jan 2011

FDA provides tentative approval under PEPFAR for Matrix's Lamivudine and Zidovudine NDA

Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Lamivudine and Zidovudine Tablets, 30 mg/60 mg.

20 Jan 2011

Perrigo to acquire Paddock Labs for $540M in cash

Perrigo Company today announced that it has signed a definitive agreement to acquire substantially all of the assets of Paddock Laboratories, Inc., a privately-held, Minneapolis-based manufacturer and marketer of generic pharmaceutical products for approximately $540 million in cash. Perrigo expects to receive a significant tax benefit as a result of the acquisition of Paddock's assets. The net present value of this tax benefit is estimated to be $95 million.

20 Jan 2011

FDA grants Soligenix Orphan Drug Designation to RiVax for prevention of ricin intoxication

Soligenix, Inc., a late-stage biopharmaceutical company, announced today that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to RiVax™ for the prevention of ricin intoxication. RiVax™ is a proprietary vaccine that contains a recombinant subunit of the A chain of ricin toxin which induces ricin neutralizing antibodies in humans and animals.

20 Jan 2011

Clinical Immunology Research Laboratory at The Mount Sinai Medical Center receives Octapharma grant

Octapharma USA today announced the second grant recipient of the Octapharma 25th Anniversary Grants Program is the Clinical Immunology Research Laboratory at The Mount Sinai Medical Center. The Octapharma Grants program supports clinical or pre-clinical research focused on human protein therapies in hematology, immune therapy, intensive care and emergency medicine.

20 Jan 2011

UnitedHealth Group reports net earnings of $4.10 per share for 2010

UnitedHealth Group today reported fourth quarter and full year 2010 financial results, including strong revenue growth from both its Health Benefits and Health Services business platforms. Full year and fourth quarter 2010 net earnings were $4.10 per share and $0.94 per share, respectively.

20 Jan 2011

Ingenix announces formation of new Life Sciences division

Ingenix, a leading provider of health care information, technology and consulting services, today announced the formation of Ingenix Life Sciences, a newly-organized division that focuses Ingenix's capabilities in assisting life sciences clients to identify, analyze and measure the value of their products.

20 Jan 2011

inVentiv Health signs definitive agreement to purchase i3 clinical development businesses from Ingenix

inVentiv Health, a leading provider of outsourced clinical development, launch and commercial services to the global health care industry, today announced it has signed a definitive agreement to purchase the i3 clinical development businesses from Ingenix.

20 Jan 2011

CHI responds to FDA recommendations for 510(k) regulatory review process

California Healthcare Institute today released a statement in response to new U.S. Food and Drug Administration (FDA) recommendations that could transform the 510(k) regulatory review process for new medical devices, greatly affecting innovation and public health in California.

20 Jan 2011

Cognizant to deliver commercial operations solutions to Lilly

Cognizant, a leading provider of consulting, technology, and business process outsourcing (BPO) services, announced that it has been selected by Eli Lilly and Company, one the world's leading innovation-driven pharmaceutical companies, to deliver an end-to-end set of services to help Lilly's U.S. sales and marketing operations be more effective, efficient, and innovative.

20 Jan 2011

BI refuses to offer increased access to AIDS drugs for low-income Americans

AHF issued the following: Despite a growing national AIDS drug crisis, pharmaceutical giant Boehringer Ingelheim Pharmaceuticals, has steadfastly refused to offer increased access to its lifesaving AIDS drugs or to respond in any way to repeated requests by AIDS Healthcare Foundation, the largest global AIDS organization, to do its part in creating a solution.

20 Jan 2011

Koronis' KP-1461 drug causes extra mutations to occur in HIV genome in HIV-infected patients

Recently published Phase 2a clinical trial results show that the frequency of specific, drug-induced mutations in the HIV genome can be significantly increased by administering KP-1461, a drug being developed by Koronis Pharmaceuticals based on its novel Viral Decay Acceleration (VDA) drug mechanism.

20 Jan 2011